



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Siltuximab

Cat. No.:	HY-P9956
CAS No.:	541502-14-1
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research <sup>[1][2][3]</sup> .	
<b>In Vivo</b>	<p>Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model<sup>[1]</sup>.</p> <p>Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells <sup>[1]</sup>
	Dosage:	10 mg/kg
	Administration:	Intraperitoneal injection; 10 mg/kg; 3 times per week
	Result:	Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells.
	Animal Model:	Female NOD-SCID mice with MCF-7 tumor <sup>[4]</sup>
	Dosage:	20 mg/kg
	Administration:	Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
	Result:	Blocked MCF-7 engraftment, induced regressions in 90% of tumors.

### REFERENCES

[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate.

---

2011 Sep 15;71(13):1455-65.

[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. *Thorax*. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.

[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. *J Thorac Oncol*. 2014 Jul;9(7):974-982.

[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor- $\alpha$ -positive breast cancer. *Breast Cancer (Dove Med Press)*. 2016 Feb 3;8:13-27.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA